Medical Student
Harvard Medical School
Eduardo Maury, PhD. Medical Student at Harvard Medical School. Incoming neurosurgery resident at Brigham and Women's Hospital.
Eduardo completed his BS in Brain and Cognitive Sciences at Massachusetts Institute of Technology in 2016 and received his PhD in Bioinformatics and Integrative Genomics from Harvard University in 2022. He will graduate with his MD from Harvard Medical School in May. He was a Jonathan • Epstein Scholar, World Congress of Psychiatric Genetics Young Investigator Award Finalist, MIT Sandbox Funding Recipient, and Paul & Daisy Soros Fellowship for New Americans Finalist. He received the F31 Fellowship, Best Basic Science Poster in Tumor Category at CNS, Larry G. Benedict Leadership Award, and was in the top 10% for the American Society of Human Genetics Reviewer's Choice Poster Award. Most recently, he won the Best Medical Student Presentation at our first annual BWH Resident Research Day in 2023. He is a member of the CNS and the American Society of Human Genetics. He obtained his PhD in Bioinformatics and Integrative Genomics in the laboratory of Christopher A. Walsh and Eunjung Alice Lee at BCH. His work focused on implementing and developing bioinformatic approaches to study the role and patterns of somatic mutations (non-inherited mutations) in neurological and neuropsychiatric disease. Using these frameworks, he found that somatic mutations, acquired during early development, contribute to the risk of schizophrenia. This finding represented a novel mechanism of neuropsychiatric disease not previously appreciated. His PhD work also revealed the presence of oncogenic somatic mutations in the normal human brain, some of which were traced back to have occurred early in development, provided insights into early brain tumor development.
Disclosure information not submitted.
Anatomical predilections and pathologic-genomics discrepancies in radiation induced meningiomas
Saturday, May 4, 2024
2:12 PM – 2:14 PM CT
Contemporary Molecular Landscape, Improved Survival, and Novel Prognostic Factors in 4,400 Gliomas
Sunday, May 5, 2024
2:45 PM – 2:47 PM CT